Pedro Macul Ferreira de Barros

Pedro Macul Ferreira de Barros

Auto-generated profile, based on publicly available information

Pedro Macul Ferreira de Barros

Department of Psychiatry, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2020 in Journal of Anxiety Disorders
Verified
Journal Article
Closed access
PBPedro Macul Ferreira de Barros
Pedro Macul Ferreira de Barros
NPNatália Polga
Natália Polga
Natalia SzejkoNatalia Szejko
Natalia Szejko
EMEurípedes Constantino Miguel
Eurípedes Constantino Miguel
JLJames Frederick Leckman
James Frederick Leckman
ELEli R. Lebowitz
Eli R. Lebowitz

19 February 2020 in European Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PDF file
PBPedro Macul Ferreira de Barros
Pedro Macul Ferreira de Barros
MRMaria Conceição Do Rosário
Maria Conceição Do Rosário
NSNatalia Szejko
Natalia Szejko
NPNatália Polga
Natália Polga
GRGuaraci de Lima Requena
Guaraci de Lima Requena
PAPedro Gomes de Alvarenga
Pedro Gomes de Alvarenga

21 February 2022 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
NPNatália Polga
Natália Polga
PBPedro Macul Ferreira de Barros
Pedro Macul Ferreira de Barros
LFLuis C. Farhat
Luis C. Farhat
KAKarla Mathias de Almeida
Karla Mathias de Almeida
MBMichael H. Bloch
Michael H. Bloch
BLBeny Lafer
Beny Lafer

1 January 2023 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
MOMarcos Vinícius Sousa de Oliveira
Marcos Vinícius Sousa de Oliveira
PBPedro Macul Ferreira de Barros
Pedro Macul Ferreira de Barros
MMMaria Alice de Mathis
Maria Alice de Mathis
RBRodrigo Boavista
Rodrigo Boavista
PCPriscila Chacon
Priscila Chacon
DCDaniel Lucas da Conceição Costa
Daniel Lucas da Conceição Costa
Objectives: To summarize evidence-based pharmacological treatments and provide guidance on clinical interventions for adult patients with obsessive-compulsive disorder (OCD).Methods: The American Psychiatric Association (APA) guidelines for the treatment of OCD (2013) were updated with a systematic review assessing the efficacy of pharmacological treatments for adult OCD, comprising monotherapy with selective serotonin reuptake inhibitors (SSRIs), clomipramine, serotonin and norepinephrine reuptake inhibitors (SNRIs), and augmentation strategies with clomipramine, antipsychotics, and glutamate-modulating agents. We searched for the literature published from 2013-2020 in five databases, considering the design of the study, primary outcome measures, types of publication, and language. Selected articles had their quality assessed with validated tools. Treatment recommendations were classified according to levels of evidence developed by the American College of Cardiology and the American Heart Association (ACC/AHA). Results: We examined 57 new studies to update the 2013 APA guidelines. High-quality evidence supports SSRIs for first-line pharmacological treatment of OCD. Moreover, augmentation of SSRIs with antipsychotics (risperidone, aripiprazole) is the most evidence-based pharmacological interven-tion for SSRI-resistant OCD. Conclusion: SSRIs, in the highest recommended or tolerable doses for 8-12 weeks, remain the first -line treatment for adult OCD. Optimal augmentation strategies for SSRI-resistant OCD include low doses of risperidone or aripiprazole. Pharmacological treatments considered ineffective or potentially harmful, such as monotherapy with antipsychotics or augmentation with ketamine, lamotrigine, or N-acetylcysteine, have also been detailed.

3 November 2024 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
PBPedro Macul Ferreira de Barros
Pedro Macul Ferreira de Barros
LFLuis C. Farhat
Luis C. Farhat
EBEmily Behling
Emily Behling
MNMadeeha Nasir
Madeeha Nasir
ALAngeli Landeros-Weisenberger
Angeli Landeros-Weisenberger
MBMichael H. Bloch
Michael H. Bloch

1 January 2023 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
MMMaria Alice de Mathis
Maria Alice de Mathis
PCPriscila Chacon
Priscila Chacon
RBRodrigo Boavista
Rodrigo Boavista
MOMarcos Vinícius Sousa de Oliveira
Marcos Vinícius Sousa de Oliveira
PBPedro Macul Ferreira de Barros
Pedro Macul Ferreira de Barros
DCDaniel Lucas da Conceição Costa
Daniel Lucas da Conceição Costa
To summarize the evidence-based cognitive-behavioral therapy (CBT) treatment and propose clinical interventions for adult patients with obsessive-compulsive disorder (OCD). A systematic review of the literature on CBT interventions for the treatment of adult OCD, comprising behavior therapy and exposure and response prevention (ERP) was done. The objective of this study is to present updated clinical guidelines to clinicians, providing comprehensive details regarding the necessary procedures to be incorporated into the CBT protocol. We searched the literature published from 2013-2020 in five databases (PubMed, Cochrane, Embase, Psycinfo and Lilacs), considering: study design, primary outcome measures, type of publication and language. Selected articles were assessed for quality with validated tools. Treatment recommendations were classified according to levels of evidence developed by the American College of Cardiology and the American Heart Association (ACC/AHA). We examined 44 new studies used to update the APA guidelines from 2013. High-quality evidence supports CBT including ERP techniques as the first-line CBT treatment for OCD. In addition, protocols for internet-delivered CBT have also demonstrated their efficacy for the treatment of adults with OCD. CBT based on ERP is a widely used treatment according to high-quality scientific evidence to treat adults with OCD.